Okimoto Niro, Nanba Fumiyo, Kibayashi Takashi, Kishimoto Michihiro, Yamato Kenji, Kurihara Takeyuki, Honda Yoshihiro, Osaki Kohichi, Asaoka Naoko
Center of Respiratory Diseases, Kawasaki Medical School, Kawasaki Hospital.
Nihon Kokyuki Gakkai Zasshi. 2008 Feb;46(2):92-5.
We studied the clinical effects of intravenous ciprofloxacin (CPFX) on community-acquired pneumonia in patients with positive Immunocard Mycoplasma test results. The subjects were 35 patients (59.4 +/- 24.8 years old) with community-acquired pneumonia with positive Immunocard Mycoplasma test results. We infused CPFX 300mg copy intravenously twice daily for 3-14 days. It was effective in 33 of 35 patients, with an efficacy rate of 94.3%. Adverse reactions consisted of itching in 2 patients, malaise in 2 patients, drug eruption in 1 patient, elevation of GPT in 1 patient and elevation of BUN in 1 patient, but all were mild. We conclude that intravenous CPFX is useful for community-acquired pneumonia in case with positive Immunocard Mycoplasma test results.
